Sun Protection Gets a Boost: Meet the New Ingredient Changing Sunscreen

When you reach for a bottle of sunscreen, you probably don’t think about the chemistry behind the label. Yet, behind every SPF number lies a cocktail of UV‑absorbing molecules that have to be vetted, tested, and—if you’re in the United States—approved by the Food and Drug Administration. After a lull that stretched back to the turn of the millennium, that process finally moved again.

On June 10 2026 the FDA published a final order in the Federal Register (35220) that added a new active ingredient to the over‑the‑counter sunscreen monograph. The molecule, called bemotrizinol—often abbreviated BEMT—can now be used at concentrations up to 6 % in U.S. sunscreens. The agency even called it the first new sunscreen active in about twenty years, the last one being approved in 1999.

So who’s behind this breakthrough? A Dutch‑Swiss giant, DSM‑Firmenich, which inherited the ingredient from DSM’s original botanical‑based sunscreen line, will launch the filter under the brand name PARSOL® Shield later in 2026. The company has secured an 18‑month exclusivity window, meaning you won’t see BEMT in other products until roughly mid‑2028.

Why does this matter? For starters, bemotrizinol is a broad‑spectrum filter that soaks up both UVA and UVB rays with a photostability that outpaces many older filters. In lab tests it retains over 95 % of its protective power after 4 hours of continuous UV exposure—something dermatologists have long wanted in a single molecule.

“In the United States, sunscreen ingredients are regulated as drugs, not cosmetics,” explains Dr. Joshua Zeichner, a board‑certified dermatologist based in New York City. “That means the approval pathway is much stricter, which is why we went so long without a new entrant.” Dr. Zeichner adds that the new filter could allow formulators to create lighter‑feel lotions without sacrificing protection.

From a consumer standpoint, the practical upshot is simple: future sunscreens may feel less greasy, have a lower risk of causing irritation, and provide steadier protection on the beach, on a bike ride, or during a quick lunch break. “People want products that work and that they enjoy using,” says Carl D’Ruiz, MPH, business‑development lead at DSM‑Firmenich. “We’ve been chasing U.S. approval for bemotrizinol since 2002, and finally getting here feels like a win for everyone.”

Not everyone is cheering without reservation, however. Environmental groups have raised the usual concerns about any new chemical entering the marine ecosystem. David Andrews, chief science officer at the Environmental Working Group, notes that “while bemotrizinol looks promising from a human‑health perspective, we’ll need solid data on its impact on coral reefs and aquatic life.” Still, early ecotoxicology studies suggest the compound degrades more quickly than legacy filters like oxybenzone.

In the grand scheme of skin health, the timing feels almost serendipitous. According to the latest projections from the American Cancer Society, roughly 65,000 men in the United States will be diagnosed with melanoma in 2026, and about 5,500 will die from it. Better sunscreen options could help curb those numbers—if people actually wear them.

Bottom line: bemotrizinol isn’t a magic bullet, but it’s a meaningful upgrade to the sunscreen toolbox. As the ingredient rolls out in the coming months, keep an eye on the label. If you see “PARSOL Shield” or “BEMT” listed, you’re likely holding one of the first U.S. sunscreens built on a filter that hasn’t been on the market here for a generation.